T-ALL cases with IL7R mutation may benefit from targeted therapeutics against JAK, MEK/Erk pathway, PI3K/Akt/mTOR pathway or BCL2 [14, 19, 62]. Here, AKT1 is linked to acute lymphoblastic leukemia.